Home

הסביבה משעמם רוב mtb treatment התפטר ערב לא ראוי

Reduced treatment delays for people with drug-resistant TB and HIV  co-infection through decentralised care and rapid Xpert MTB/RIF test |  aidsmap
Reduced treatment delays for people with drug-resistant TB and HIV co-infection through decentralised care and rapid Xpert MTB/RIF test | aidsmap

Tuberculosis Drug Discovery: Challenges and New Horizons | Journal of  Medicinal Chemistry
Tuberculosis Drug Discovery: Challenges and New Horizons | Journal of Medicinal Chemistry

Four-Month Rifapentine Regimens with or without Moxifloxacin for  Tuberculosis | NEJM
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis | NEJM

Juliana Furtado Gets the Lower-link VPP Treatment - Mountain Bike Press  Release - Vital MTB
Juliana Furtado Gets the Lower-link VPP Treatment - Mountain Bike Press Release - Vital MTB

Therapeutic host-directed strategies to improve outcome in tuberculosis |  Mucosal Immunology
Therapeutic host-directed strategies to improve outcome in tuberculosis | Mucosal Immunology

4.2 Adult and adolescent algorithms | MSF Medical Guidelines
4.2 Adult and adolescent algorithms | MSF Medical Guidelines

PDF] Nitric Oxide in the Pathogenesis and Treatment of Tuberculosis |  Semantic Scholar
PDF] Nitric Oxide in the Pathogenesis and Treatment of Tuberculosis | Semantic Scholar

Assessment of tuberculosis disease activity in people infected with  Mycobacterium tuberculosis and living with HIV: A longitudinal cohort study  - eClinicalMedicine
Assessment of tuberculosis disease activity in people infected with Mycobacterium tuberculosis and living with HIV: A longitudinal cohort study - eClinicalMedicine

Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient  tuberculosis drug-susceptibility testing? - The Lancet Infectious Diseases
Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing? - The Lancet Infectious Diseases

Mycobacterium tuberculosis clinical isolates carry mutational signatures of  host immune environments | Science Advances
Mycobacterium tuberculosis clinical isolates carry mutational signatures of host immune environments | Science Advances

Prevalence of Mycobacterium tuberculosis (Rifampicin-Resistant MTB) and  Associated Risk Actors Among Pulmonary Presumptive TB Patients in Eastern  Amhara, Ethiopia: 2015–2019 | SpringerLink
Prevalence of Mycobacterium tuberculosis (Rifampicin-Resistant MTB) and Associated Risk Actors Among Pulmonary Presumptive TB Patients in Eastern Amhara, Ethiopia: 2015–2019 | SpringerLink

Tuberculosis treatment outcomes among people living with HIV diagnosed  using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a  stepped-wedge cluster randomised trial | BMC Infectious Diseases | Full Text
Tuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial | BMC Infectious Diseases | Full Text

Role of empiric treatment in hospitalized patients with Xpert MTB/RIF-negative  presumptive pulmonary tuberculosis: A prospective cohort study -  International Journal of Infectious Diseases
Role of empiric treatment in hospitalized patients with Xpert MTB/RIF-negative presumptive pulmonary tuberculosis: A prospective cohort study - International Journal of Infectious Diseases

New agents for the treatment of drug-resistant Mycobacterium tuberculosis -  ScienceDirect
New agents for the treatment of drug-resistant Mycobacterium tuberculosis - ScienceDirect

A long-acting formulation of rifabutin is effective for prevention and  treatment of Mycobacterium tuberculosis
A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis

Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled  two-center study | BMC Infectious Diseases | Full Text
Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study | BMC Infectious Diseases | Full Text

Weakening Tuberculosis Bacteria's Defenses May Speed Treatment and Thwart  Drug Resistance | Newsroom | Weill Cornell Medicine
Weakening Tuberculosis Bacteria's Defenses May Speed Treatment and Thwart Drug Resistance | Newsroom | Weill Cornell Medicine

Frontiers | Molecular Diagnosis of Drug-Resistant Tuberculosis; A  Literature Review
Frontiers | Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review

Figure 3 - Decreased Time to Treatment Initiation for Multidrug-Resistant  Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia - Volume 22,  Number 3—March 2016 - Emerging Infectious Diseases journal - CDC
Figure 3 - Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia - Volume 22, Number 3—March 2016 - Emerging Infectious Diseases journal - CDC

Evaluation of Xpert MTB-RIF guided diagnosis and treatment of  rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort  study | PLOS ONE
Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study | PLOS ONE

Summary of HIV-MTB co-infection and treatment scenarios. | Download Table
Summary of HIV-MTB co-infection and treatment scenarios. | Download Table

Tuberculosis: Past, present and future of the treatment and drug discovery  research - ScienceDirect
Tuberculosis: Past, present and future of the treatment and drug discovery research - ScienceDirect